Trial Information
Inclusion Criteria:
- Myeloma in remission
Exclusion Criteria:
- Adverse events (AEs) to statin, already on a statin, or contraindication to statin
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Principal Investigator
Andrew Spencer, MBChB, FRACP, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
The Alfred
Authority:
Australia: Department of Health and Ageing Therapeutic Goods Administration
Study ID:
7/04
NCT ID:
NCT00164086
Start Date:
Completion Date:
Related Keywords:
- Myeloma
- Multiple Myeloma
- Neoplasms, Plasma Cell
